Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 8/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3718111 | 0.92 | ALDH1A1 (0.56) | PRMT5WDR77TMEM97SIGMAR1NOTUM | |
| SCHEMBL30023801 | 0.83 | NOTUM (0.58) | PRMT5WDR77NOTUMALDH1A1ABHD6 | |
| SCHEMBL16268868 | 0.82 | ALDH1A1 (0.64) | PRMT5WDR77NOTUMALDH1A1ABHD6 | |
| SCHEMBL30647004 | 0.81 | PRMT5 (0.55) | PRMT5WDR77NOTUMALDH1A1ABHD6 | |
| SCHEMBL15355387 | 0.81 | PRMT5 (0.55) | PRMT5WDR77NOTUMALDH1A1ABHD6 | |
| SCHEMBL9527451 | 0.81 | PRMT5 (0.57) | PRMT5WDR77NOTUMPOLBABHD6 | |
| SCHEMBL22784699 | 0.80 | HDAC3 (0.60) | NOTUMALDH1A1HRH3HPGDTSHR | |
| SCHEMBL9853000 | 0.80 | SMN1; SMN2 (0.58) | PRMT5WDR77TMEM97SIGMAR1NOTUM | |
| SCHEMBL3662555 | 0.79 | NPC1 (0.60) | PRMT5WDR77NOTUMALDH1A1HRH3 | |
| SCHEMBL29698165 | 0.79 | PRMT5 (0.59) | PRMT5WDR77NOTUMHRH3ABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | claimed |
| EP-2227461-A1 | NEW COMPOUNDS III | AstraZeneca AB (Publ) (SE) | 2010-09-15 | — | — | EP | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| US-20090176798-A1 | New compounds III | BIOVITRUM AB (SE) | 2009-07-09 | — | — | US | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071677-A1 | NEW COMPOUNDS III | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176798-A1 | New compounds III | GPR119, FABP4, GLP1R | PRMT5 1890/4885WDR77 2024/4885TMEM97 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.